1. King H, Aubert RE, Herman WH.Global burden of diabetes, 1995–2025: prevalence, numerical estimates, and projections. Diabetes Care1998;21:1414–31.
2.
2. Amos AF, McCarty DJ, Zimmet P.The rising global burden of diabetes and its complications: estimates and projections to the year 2010. Diabet Med1997;14(suppl 5):S1–S85.
3.
3. Aronson D, Rayfield EJ, Chesebro JH.Mechanisms determining course and outcome of diabetic patients who have had acute myocardial infarction. Ann Intern Med1997;126:296–306.
4.
4. Roffi M, Chew DP, Mukherjee D et al.Platelet glycoprotein IIb/IIIa inhibitors reduce mortality in diabetic patients with non-ST-segment-elevation acute coronary syndromes. Circulation2001;104:2767–71.
5.
5. Anonymous.Indications for ACE inhibitors in the early treatment of acute myocardial infarction: systematic overview of individual data from 100, 000 patients in randomized trials. ACE Inhibitor Myocardial Infarction Collaborative Group. Circulation1998;97:2202–12.
6.
6. Anonymous.A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee. Lancet1996;348:1329–39.
7.
7. Bhatt DL, Marso SP, Hirsch AT, Ringleb PA, Hacke W, Topol EJ.Amplified benefit of clopidogrel versus aspirin in patients with diabetes mellitus. Am J Cardiol2002;90:625–8.
8.
8. Norhammar A, Tenerz A, Nilsson G et al.Glucose metabolism in patients with acute myocardial infarction and no previous diagnosis of diabetes mellitus: a prospective study. Lancet2002;359:2140–4.
